Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of naldemedine for constipation associated with Parkinson's disease
jRCT2031260060Phase 2Recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing Naldemedine with Placebo (2 arms). Primary endpoint: Change from baseline in the number of spontaneous bowel movements within 24 hours after the first administration. Started May 2026; status: recruiting.
02
Drugs
naldemedine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on jRCT2031260060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260060.